GlassScriptPhysician profile
Brian M Lipes
NPI 1629008685
$4,886.95
in general payments reported to CMS, 2019-2025
47 companies · $1,786 in 2025
The $1,786 reported for 2025 was more than what 92% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $553 · 2023: $2,141 · 2024: $407 · 2025: $1,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,923 · Education: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,922.51 |
| Education | $410.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $734.11 | 2022-2025 | Darzalex, Rybrevant, Erleada |
| Celgene Corporation | $357.24 | 2022-2025 | Opdualag, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $273.82 | 2023-2025 | Tagrisso, Calquence, Lynparza |
| Merck Sharp & Dohme LLC | $271.64 | 2022-2025 | Keytruda, Welireg |
| Novartis Pharmaceuticals Corporation | $269.76 | 2023-2025 | Kisqali |
| Astellas Pharma US INC | $264.06 | 2023-2025 | Padcev, Cresemba |
| Eisai INC. | $251.55 | 2022-2025 | |
| Pfizer INC. | $189.01 | 2022-2025 | |
| Daiichi Sankyo INC. | $174.46 | 2022-2023 | Enhertu |
| Seagen INC. | $165.11 | 2023-2025 | Padcev |
| Abbvie INC. | $160.97 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.51 | 2023-2025 | Opdivo |
| Amgen INC. | $123.15 | 2022-2023 | Lumakras, Kyprolis, Blincyto |
| Karyopharm Therapeutics INC. | $112.85 | 2023-2025 | Xpovio |
| Incyte Corporation | $103.50 | 2022-2025 | Pemazyre, Monjuvi, Jakafi |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $93.55 | 2023-2025 | Tecentriq, Alecensa, Phesgo |
| Alexion Pharmaceuticals, INC. | $77.44 | 2025 | Ultomiris |
| Puma Biotechnology, INC. | $75.70 | 2023-2025 | |
| Agios Pharmaceuticals, INC. | $74.67 | 2024 | Pyrukynd |
| Tersera Therapeutics LLC | $69.82 | 2023-2025 | Zoladex |
| Genzyme Corporation | $66.84 | 2023 | |
| Adaptive Biotechnologies Corporation | $62.70 | 2022-2023 | Clonoseq |
| Pharmacyclics LLC, An Abbvie Company | $60.00 | 2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $59.77 | 2023-2024 | Fruzaqla, Iclusig, Ninlaro |
| Lilly USA, LLC | $50.11 | 2023 | Jaypirca, Retevmo, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $49.81 | 2022-2023 | |
| Regeneron Healthcare Solutions, INC. | $48.61 | 2023 | Libtayo |
| Pharmacosmos Therapeutics INC. | $47.54 | 2023 | Monoferric |
| Emd Serono, INC. | $42.59 | 2023 | Bavencio |
| Genmab U.S., INC. | $39.97 | 2023 | Tivdak |
| Glaxosmithkline, LLC. | $36.03 | 2022 | |
| Gilead Sciences, INC. | $33.94 | 2023 | |
| Apellis Pharmaceuticals, INC. | $33.20 | 2023-2025 | Empaveli |
| Ipsen Biopharmaceuticals, INC | $29.96 | 2025 | Tazverik |
| Geron Corporation | $29.39 | 2024 | Rytelo |
| Taiho Oncology, INC. | $25.92 | 2023 | |
| Foundation Medicine, INC. | $24.84 | 2023 | |
| Sumitomo Pharma America, INC. | $21.86 | 2025 | Orgovyx |
| Telix Pharmaceuticals | $21.43 | 2023 | Illuccix |
| Rigel Pharmaceuticals, INC. | $20.50 | 2023 | Tavalisse, Rezlidhia |
| Array Biopharma INC | $20.36 | 2023 | Mektovi, Xalkori, Lorbrena |
| Immunocore Limited | $18.77 | 2025 | Kimmtrak |
| Mirati Therapeutics, INC. | $17.18 | 2023 | Krazati |
| Ibsa Pharma INC. | $16.04 | 2023 | Tirosint, Licart |
| Myriad Genetic Laboratories, INC. | $15.84 | 2023 | Myrisk |
| Exelixis INC. | $14.60 | 2025 | Cabometyx |
| Morphosys, US INC. | $12.23 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Lipes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.